Trial record 5 of 466 for:    pharmacology + NICHD

Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation (AMIGOS)

This study has been completed.
Sponsor:
Collaborators:
Penn State University
University of Colorado, Denver
University of Michigan
University of Pennsylvania
University of Texas
University of Vermont
Wayne State University
Information provided by (Responsible Party):
Heping Zhang, Yale University
ClinicalTrials.gov Identifier:
NCT01044862
First received: January 7, 2010
Last updated: June 2, 2014
Last verified: June 2014
  Purpose

The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low rates of multiple gestations. The central hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly reducing the numbers of multiple gestational pregnancies that result from stimulation with clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed research is that reduction of multiple pregnancy rates could significantly reduce maternal and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals and society.


Condition Intervention Phase
Pregnancy
Unexplained Infertility
Drug: Letrozole (aromatase inhibitor)
Drug: Clomiphene Citrate
Drug: Follicle Stimulating Hormone (gonadotropin)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Multiple gestation rate following recruitment of multiple follicular development with an AI, as compared to CC and FSH. [ Time Frame: January 2010 to January 2012 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Rate of pregnancy obtained [ Time Frame: January 2010 to January 2012 ] [ Designated as safety issue: No ]
  • Time to pregnancy [ Time Frame: January 2010 to January 2012 ] [ Designated as safety issue: No ]
  • Live birth rate [ Time Frame: January 2010 to January 2012 ] [ Designated as safety issue: No ]

Enrollment: 900
Study Start Date: June 2010
Study Completion Date: March 2014
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Aromatase Inhibitors (AI)
A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Drug: Letrozole (aromatase inhibitor)
A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Active Comparator: Clomiphene Citrate (CC)
CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Drug: Clomiphene Citrate
CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Active Comparator: Follicle Stimulating Hormone (FSH)
A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Drug: Follicle Stimulating Hormone (gonadotropin)
A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.

Detailed Description:

Patient Population

The population will consist of 900 women up to and including women ≥18 to ≤40 years years of age (at time of randomization) desirous of conceiving who will be recruited over approximately a two year period from the Reproductive Medicine Network (RMN) clinical sites and possibly from the Specialized Cooperative Center Programs in Reproductive Research (SCCPIR) sites, through public notification programs.

Study Design

This will be a multi-center, prospective, partially blinded clinical trial of gonadotropins vs. clomiphene citrate vs. aromatase inhibitors. The randomization scheme will be coordinated through the data coordination center (DCC) and the randomization will be stratified by each participating site and within each site for ages 18-34 and 35-40.

Treatment

Patients will be randomized to receive either FSH, CC, or an AI according to randomization tables generated by a computer randomization program. Treatment assignments will be blocked by site and age group. Subjects randomized to pill treatment will receive medication in double blinded fashion, receiving one type of pill (overcoated CC or AI). Subjects randomized to injectable medication(FSH) will receive vials of medication.

Primary efficacy parameter

Multiple gestation rate following recruitment of multiple follicular development with an AI, as compared to CC and FSH.

Secondary efficacy parameters

Rate of pregnancy obtained, live birth rate, and time to pregnancy following administration of an aromatase inhibitor, as compared to CC and FSH as well as the live birth rate of multiple gestation pregnancies.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women ≥18 to ≤40 years of age, with one or more years infertility history, desirous of conceiving, regularly ovulating (defined as 9 or more menses per year), at initiation of participation.
  2. Normal uterine cavity and at least one open fallopian tube confirmed by hysterosalpingography (HSG), sonohysterography, or laparoscopy/hysteroscopy in the last three years preceding enrollment into the study. An uncomplicated intrauterine non-IVF pregnancy and uncomplicated delivery and postpartum course resulting in live birth within the last three years will also serve as sufficient evidence of a patent tube and normal uterine cavity as long as the subject did not have, during the pregnancy or subsequently, risk factors for Asherman's syndrome or tubal disease or other disorder leading to an increased suspicion for intrauterine abnormality or tubal occlusion.
  3. Evidence of ovarian function/reserve as assessed by day 3 (+/-2 days) FSH ≤12 IU/L within one year prior to study initiation.
  4. Normal or corrected thyroid function within one year of study initiation.
  5. Normal prolactin level within one year of study initiation.
  6. In general good health, not taking any medications which could interfere with the study (e.g., FSH, insulin sensitizers).
  7. Ability to have inseminations following hCG administration.
  8. Male partner with total motile sperm in the ejaculate of at least 5 million sperm, within one year of study initiation.

Exclusion Criteria:

  1. Currently pregnant or successful pregnancies within 12 months of initiating participation. Clinical intrauterine miscarriages prior to initiating participation, within ASRM guidelines: subjects over 35 must wait six months, while subjects under 35 must wait 12 months. No exclusion for biochemical pregnancies.
  2. Undiagnosed abnormal uterine bleeding.
  3. Suspicious ovarian mass.
  4. Patients on oral contraceptives, depo-progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially when the implants are still in place. A one-month washout will be required for patients on oral cyclic progestins.
  5. Known 21-hydroxylase deficiency or other enzyme defect causing congenital adrenal hyperplasia.
  6. Type I or Type II diabetes mellitus, or if receiving antidiabetic medications.
  7. Known significant anemia (Hemoglobin <10 g/dL).
  8. History of deep venous thrombosis, pulmonary embolus, or cerebrovascular event.
  9. Known heart disease (New York Heart Association Class II or higher).
  10. Known Liver disease (defined as AST or ALT>2 times normal, or total bilirubin >2.5 mg/dL).
  11. Known Renal disease (defined as BUN >30 mg/dL or serum creatinine > 1.4 mg/dL).
  12. History of, or suspected cervical carcinoma, endometrial carcinoma or breast carcinoma.
  13. History of alcohol abuse (defined as >14 drinks/week) or binge drinking of ≥ 6 drinks at one time).
  14. Known Cushing's disease.
  15. Known or suspected adrenal or ovarian androgen secreting tumors.
  16. Allergy or contraindication to the treatment medications: AI, gonadotropins, CC or hCG.
  17. Couples with previous sterilization procedures (e.g. vasectomy, tubal ligation) which have been reversed.
  18. Patients with untreated poorly controlled hypertension defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
  19. Subjects who have undergone a bariatric surgery procedure in the recent past (< 12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
  20. Known moderate or severe endometriosis
  21. Known polycystic ovarian syndrome as evidenced by anovulation or oligoovulation, hirsutism and/or elevated testosterone levels, and ovarian morphology on ultrasound examination.
  22. Donated semen.
  23. Couples in which either partner is legally married to someone else.
  24. Medical conditions that are contraindications to pregnancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01044862

Locations
United States, Alabama
University of Alabama Birmingham
Birmingham, Alabama, United States, 35249-7333
United States, California
University of California, San Francisco
San Francisco, California, United States, 94115
Stanford University Medical Center
Stanford, California, United States, 94305-5317
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06511
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48108
Wayne State University
Detroit, Michigan, United States, 48201
United States, New Jersey
University of Medicine and Dentistry of New Jersey
Newark, New Jersey, United States, 07601
United States, North Carolina
Carolinas Medical Center
Charlotte, North Carolina, United States, 28232-2861
United States, Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Pennsylvania State University College of Medicine
Hershey, Pennsylvania, United States, 17033
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78207
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05405
Sponsors and Collaborators
Yale University
Penn State University
University of Colorado, Denver
University of Michigan
University of Pennsylvania
University of Texas
University of Vermont
Wayne State University
Investigators
Study Director: Esther Eisenberg, MD, MPH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Chair: Nanette Santoro, MD Albert Einstein College of Medicine of Yeshiva University
Principal Investigator: Michael Diamond, MD Wayne State University
Study Director: Richard Legro, MD Pennsylvania State University College of Medicine
Study Director: William Schlaff, MD University of Colorado Denver Health Science Center
Study Director: Gregory Christman, MD University of Michigan
Study Director: Christos Coutifaris, MD University of Pennsylvania
Study Director: Robert Brzyski, MD, PhD The University of Texas Health Science Center at San Antonio
Study Director: Peter Casson, MD University of Vermont
Study Director: Heping Zhang, PhD Yale University
  More Information

Additional Information:
No publications provided

Responsible Party: Heping Zhang, Principal Investigator, Yale University
ClinicalTrials.gov Identifier: NCT01044862     History of Changes
Other Study ID Numbers: RMN-AMIGOS, 3U10HD055925-02S1, 5U10HD055925, 3U10HD039005-08S1, 5U10HD039005
Study First Received: January 7, 2010
Last Updated: June 2, 2014
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Yale University:
Pregnancy
Infertility
Ovarian stimulation
Aromatase inhibitors
Follicle Stimulating Hormone

Additional relevant MeSH terms:
Pharmacologic Actions
Molecular Mechanisms of Pharmacological Action
Infertility
Genital Diseases, Male
Genital Diseases, Female
Clomiphene
Follicle Stimulating Hormone
Hormones
Letrozole
Aromatase Inhibitors
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Therapeutic Uses
Selective Estrogen Receptor Modulators
Antineoplastic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 22, 2014